Company Overview and News
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
KMI.WS ECOR PLNT KMI.PRA PKG AEP NINE ADT GE COF-P GILD TMUS PDYPF SYF XERS JNJ VZ MSFT ADS KZR NNN EIDX FB RF.PRB AVRO RF.PRA HOPE NFLX AXP EHC BAC COF-D SEAS COF-C COF-F KR KS IIIV PNFP AAPL DDOC AEP.PRA SJM INPAP SIX JPM GNE WRK LGEJY KMRFZ DE 39IB KMX COF.WS RF UAL WMT CFIN LGEAF IP AMZN MGTA NTRS HON KMI CIWV GM.WS.A GM.WS.B HCSG GM.WS.C KMR CVB VLKAY LGEIY EBAY EPRT STT SLB BAC DFS LGEPF STM BBY BX BK STM LTXB LGLD SLB GM.WSB FOXA CLW COF.PRG COF.PRH PM STT.PRC STT.PRE NTRSP STT.PRD STT.PRG AUTL COF.PRP DLPH SWKS GS SWK TRTX GM PII COF.PRC COF.PRD DIS NEE COF.PRF IBM MOR F GEC C CMCSA COF FUN FUL CFG HBAN NEE.PRI XEL NEE.PRJ TGT BLK S PPG T NEE.PRC NEE.PRQ NEE.PRR SNE DPZ
Investors have been finding it harder to generate positive returns in 2018 than in 2017 and the few prior years. The bull market is effectively nine years old, and trade wars, rising interest rates and a slowdown in some of the expectations of global growth are some of the variables making it more difficult for investors to decide how to best position their investment portfolio.
BLK CATR CAT TRI DE
But recently, the equity research team at Goldman compiled a list of stocks within the company’s coverage universe that have the most potential upside to their price targets. The list is long (about 40 stocks), and Goldman pegs all of them as having roughly 30% or more upside to their price target.
LRCX CAT RCL NVDA MAR.WI CFIN NOC TSNU IP JEC CIWV TSN NCLH SCHW.PRBCL TDG INPAP DWDP CFG MAR SCHW MU BWA HRS WRK DE
As the human family increases toward 10 billion, the chemical-agricultural industrial food system, based on monoculture crops and meat diets, is proving unsustainable.
CAT ADM DE
Dividend investing at its finest! I thought now would be a great time to reflect on what has occurred over the last six months in the dividend income portfolio of mine. I do not mean just any old reflection, but I am going to be specifically talking about dividend increases and what the impact has been on my portfolio this year. Tax reform has truly showed its colors and companies have been sending the savings, or a part of, to their shareholders.
PM KR KMI.PRA KMI JNJ CAT KMI.WS KMR KMRFZ CVB DE
Another month up and another month down. As I'm writing this on June 1, I could see new flurries of dividends hitting my account. The sun is definitely heating up here in Cleveland, the Cavs are in the finals and were just robbed a Game 1 road victory. I love writing these reports, as the comparison to prior year, really hits home when you see the hard work that has been put in place to improve. Did I continue to push the limits for May of 2018 dividend income? Let's find out!
HRL PGP PG O.PRF O OPRF DE
The first half of 2018 hasn’t been easy. And there’s no promise that the second half of the year will be any easier. Far from it. Market commentators still can’t decide whether the bull market is here to stay or whether a bear market is lurking just around the corner.
TGTX LOXO MS.PRE MS.PRF MS.PRG MS.PRA LOGM MS.PRI GM.WS.A MS.PRK GM.WS.B DG GM.WS.C TSLA GM MS GM.WSB DAL DE
Markets fell last week upon the expansion of the so-called “Trump tariffs.” The uncertainty created by the new round of duties — 25% on imported steel and 10% on imported aluminum — exacerbated long-running fears of a trade war.
X STLD CATR CAT AKS HOG DE
The S&P 500 Index edged higher last week after investors reacted positively to another strong report on the U.S. labor market. With corporate profits heading higher, several companies rewarded shareholders with news of fresh dividend raises.
SAR UVE SAB SAQ LADR DE
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to DE / Deere & Co. on message board site Silicon Investor.
as of ET